After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
